Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Investigational new drugs - 1 Oct 2015

Protsenko Svetlana A, Semionova Anna I, Komarov Yuri I, Aleksakhina Svetlana N, Ivantsov Alexandr O, Iyevleva Aglaya G, Imyanitov Evgeny N

Abstract excerpt

We report a patient with a metastatic relapse of clear cell sarcoma, whose tumor harbored BRAF V600E mutation. Standard chemotherapy with doxorubicin and ifosfamide failed to slow the disease progression. Subsequent administration of vemurafenib (960 mg twice a day) resulted in complete tumor response after 8 weeks of treatment. Literature data on the use of vemurafenib and dabrafenib in non-melanoma BRAF-mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRAF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 26286452
DOI: 10.1007/s10637-015-0280-0

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.PMID 26286452Read ↗

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.Semantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.Semantic proximity Read ↗

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.Semantic proximity Read ↗

BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.Semantic proximity Read ↗

Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations.Semantic proximity Read ↗

Vemurafenib: a guide to its use in unresectable or metastatic melanoma.Semantic proximity Read ↗

Vemurafenib and radiation therapy in melanoma brain metastases.Semantic proximity Read ↗

BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review.Semantic proximity Read ↗

Successful Treatment of Metastatic Upper Tract Urothelial Carcinoma With Vemurafenib: Case Report.Semantic proximity Read ↗

Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.